CrossrefInfokarte
Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial
Breast Cancer Research and Treatment · 2026-11 · 220 (1)
DOI: 10.1007/s10549-026-08091-4 ↗Abstract
Kein Abstract verfügbar.
EUVIMED